Compare ClearPoint Neuro Inc (CLPT) vs Oklo Inc (OKLO) Price & Performance

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

OKLO stock trades at $45.81, down 6.22% in the last session, reflecting ongoing volatility. The company shows strong analyst support with 77% buy ratings and a $90.88 consensus price target, but faces fundamental challenges with negative ROE (-8.87%) and net income (-$105.66M). Recent DOE approval for the Groves Isotope Test Reactor represents a key regulatory milestone, though cash flow remains heavily dependent on financing activities.

The outlook balances significant growth potential in nuclear energy against substantial execution risks. While analyst targets suggest 98% upside, the company must navigate regulatory hurdles and achieve profitability amid negative earnings trends. The stock's bearish technical signals and high valuation multiples require careful risk assessment by investors.